Antibodies against epidermal growth factor receptor (EGFR) and uses thereof
Anti-EGFR antibodies, therapeutic compositions comprising combinations of anti-EGFR antibodies, as well as methods for using such antibodies and compositions to treat EGFR-related disorders (e.g., cancers), are disclosed.
1. A monoclonal antibody which binds EGFR extracellular domain and comprises heavy and light chain CDR1, CDR2, and CDR3 sequences, wherein the heavy and light chain CDR1, CDR2, and CDR3 sequences are selected from the group consisting of:
(a) heavy chain CDR1, CDR2, and CDR3 sequences of SEQ ID NOs: 1, 2, and 3 respectively, and light chain CDR1, CDR2, and CDR3 sequences of SEQ ID NOs: 4, 5, and 6, respectively;
(b) heavy chain CDR1, CDR2, and CDR3 sequences of SEQ ID NOs: 7, 8, and 9, respectively, and light chain CDR1, CDR2, and CDR3 sequences of SEQ ID NOs: 10, 11 and 12, respectively; and
(c) heavy chain CDR1, CDR2, and CDR3 sequences of SEQ ID NOs: 13, 14, and 15, respectively, and light chain CDR1, CDR2, and CDR3 sequences of SEQ ID NOs: 16, 17, and 18, respectively.
2. A monoclonal antibody that binds to EGFR extracellular domain and comprises a heavy chain variable region and a light chain variable region, wherein the heavy and light chain variable region sequences are selected from the group consisting of:
(a) a heavy chain variable region comprising SEQ ID NO: 19 and a light chain variable region comprising SEQ ID NO: 20;
(b) a heavy chain variable region comprising SEQ ID NO: 21 and a light chain variable region comprising SEQ ID NO: 22; and
(c) a heavy chain variable region comprising SEQ ID NO: 23 and a light chain variable region comprising SEQ ID NO: 24.
3. The monoclonal antibody of claim 1 , which binds to EGFR with a K D of better than 100 nM.
4. The monoclonal antibody of claim 1 , which is a human antibody.
5. The monoclonal antibody of claim 1 , wherein the antibody is selected from the group consisting of a bispecific antibody, immunoconjugate, Fab, Fab′2, ScFv, avimer, nanobody and a domain antibody.
6. The monoclonal antibody of claim 1 , wherein the monoclonal antibody is selected from the group consisting of IgG1, IgG2, IgG3, IgG4, IgM, IgA1, IgA2, IgAsec, IgD and IgE isotype antibodies.
7. A pharmaceutical composition comprising the monoclonal antibody of claim 1 and a pharmaceutically acceptable carrier.
8. A kit comprising the pharmaceutical composition of claim 7 in a container.
9. The monoclonal antibody of claim 1 for the treatment of a cancer.
10. A composition comprising two or three monoclonal antibodies which bind to EGFR extracellular domain, wherein the two or three monoclonal antibodies are selected from the group consisting of:
(a) a monoclonal antibody comprising heavy chain CDR1, CDR2, and CDR3 sequences of SEQ ID NOs: 1, 2, and 3 respectively, and light chain CDR1, CDR2, and CDR3 sequences of SEQ ID NOs: 4, 5, and 6, respectively;
(b) a monoclonal antibody comprising heavy chain CDR1, CDR2, and CDR3 sequences of SEQ ID NOs: 7, 8, and 9, respectively, and light chain CDR1, CDR2, and CDR3 sequences of SEQ ID NOs: 10, 11 and 12, respectively and
(c) a monoclonal antibody comprising heavy chain CDR1, CDR2, and CDR3 sequences of SEQ ID NOs: 13, 14, and 15, respectively, and light chain CDR1, CDR2, and CDR3 sequences of SEQ ID NOs: 16, 17 and 18, respectively;
and wherein the composition comprises (a) and (b), (a) and (c), (b) and (c) or (a), (b) and (c).
11. A composition comprising two or three monoclonal antibodies which bind to EGFR extracellular domain, wherein the two or three monoclonal antibodies are selected from the group consisting of:
(a) a monoclonal antibody comprising a heavy chain variable region comprising SEQ ID NO: 19 and a light chain variable region comprising SEQ ID NO: 20;
(b) a monoclonal antibody comprising a heavy chain variable region comprising SEQ ID NO: 21 and a light chain variable region comprising SEQ ID NO: 22; and
(c) a monoclonal antibody comprising a heavy chain variable region comprising SEQ ID NO: 23 and a light chain variable region comprising SEQ ID NO: 24;
and wherein the composition comprises (a) and (b), (a) and (c), (b) and (c) or (a) (b) and (c).
12. The composition of claim 10 , wherein each of monoclonal antibodies (a), (b) and (c) binds to EGFR with a K D of better than 100 nM.
13. The composition of claim 12 , wherein each of monoclonal antibodies (a), (b) and (c) binds to EGFR with a K D of better than 10 nM.
14. The composition of claim 10 , wherein each of monoclonal antibodies (a), (b) and (c) is a human antibody.
15. The composition of claim 10 , wherein one or more of monoclonal antibodies (a), (b), and (c) is independently selected from the group consisting of a bispecific antibody, immunoconjugate, Fab, Fab′2, ScFv, avimer, nanobody and a domain antibody.
16. The composition of claim 10 , wherein each of monoclonal antibodies (a), (b), and (c) is independently selected from the group consisting of IgG1, IgG2, IgG3, IgG4, IgM, IgA1, IgA2, IgAsec, IgD and IgE isotype antibodies.
17. The composition of claim 10 , which further comprises a pharmaceutically acceptable carrier.
18. A kit comprising the composition of claim 17 in a container.
19. The composition of claim 10 for the treatment of a cancer.
20. A composition comprising three monoclonal anti-EGFR antibodies, said composition comprising a first antibody, a second antibody and a third antibody, wherein (i) the first antibody comprises heavy chain CDR1, CDR2, and CDR3 sequences of SEQ ID NOs: 1, 2, and 3 respectively, and light chain CDR1, CDR2, and CDR3 sequences of SEQ ID NOs: 4, 5, and 6, respectively; (ii) the second antibody comprises heavy chain CDR1, CDR2, and CDR3 sequences of SEQ ID NOs: 7, 8, and 9, respectively, and light chain CDR1, CDR2, and CDR3 sequences of SEQ ID NOs: 10, 11 and 12, respectively; and (iii) the third antibody comprises heavy chain CDR1, CDR2, and CDR3 sequences of SEQ ID NOs: 13, 14, and 15 respectively, and light chain CDR1, CDR2, and CDR3 sequences of SEQ ID NOs: 16, 17, and 18, respectively, and wherein the first second and third antibodies are present at a molar ratio of 2:2:1 to each other.
21. A composition comprising three monoclonal anti-EGFR antibodies, said composition comprising a first antibody, a second antibody and a third antibody, wherein (i) the first antibody comprises a heavy chain variable region comprising SEQ ID NO: 19 and a light chain variable region comprising SEQ ID NO: 20; (ii) the second antibody comprises a heavy chain variable region comprising SEQ ID NO: 21 and a light chain variable region comprising SEQ ID NO: 22; and (iii) the third antibody comprises a heavy chain variable region comprising SEQ ID NO: 23 and a light chain variable region comprising SEQ ID NO: 24, and wherein the first second and third antibodies are present at a molar ratio of 2:2:1 to each other.
22. The composition of claim 20 , wherein each of the first antibody, the second antibody and the third antibody binds to EGFR with a K D of better than 100 nM.
23. The composition of claim 20 , wherein the first antibody binds to EGFR with a K D in a range of 1×10 −9 M to 1.1×10 −11 M, the second antibody binds to EGFR with a K D in a range of 1×10 −9 M to 7.0×10 −11 M and the third antibody binds to EGFR with a K D in a range of 1×10 −9 M to 3.6×10 −10 M.
24. The composition of claim 20 , wherein each of the first antibody, the second antibody and the third antibody are human antibodies.
25. The composition of claim 20 , wherein one or more of the first antibody, the second antibody and the third antibody are independently selected from the group consisting of a bispecific antibody, immunoconjugate, Fab, Fab′2, ScFv, avimer, nanobody and a domain antibody.
26. The composition of claim 20 , wherein each of the first antibody, the second antibody and the third antibody is independently selected from the group consisting of IgG1, IgG2, IgG3, IgG4, IgM, IgA1, IgA2, IgAsec, IgD and IgE isotype antibodies.
27. The composition of claim 20 , which further comprises a pharmaceutically acceptable carrier.
28. The composition of claim 27 , which is a sterile composition and/or suitable for injection.
29. The composition of claim 27 , which is a sterile composition suitable for intravenous injection.
30. A kit comprising the composition of claim 27 in a container.
31. The composition of claim 20 for the treatment of a cancer.
32. The monoclonal antibody of claim 1 , wherein the heavy chain CDR1, CDR2, and CDR3 sequences comprise SEQ ID NOs: 1, 2, and 3 respectively, and the light chain CDR1, CDR2 and CDR3 sequences comprise SEQ ID NOs: 4, 5, and 6, respectively.
33. The monoclonal antibody of claim 1 , wherein the heavy chain CDR1, CDR2, and CDR3 sequences comprise SEQ ID NOs: 7, 8, and 9, respectively, and the light chain CDR1, CDR2, and CDR3 sequences comprise SEQ ID NOs: 10, 11 and 12, respectively.
34. The monoclonal antibody of claim 1 , wherein the heavy chain CDR1, CDR2, and CDR3 sequences comprise SEQ ID NOs: 13, 14, and 15, respectively, and the light chain CDR1, CDR2, and CDR3 sequences comprise SEQ ID NOs: 16, 17, and 18, respectively.
35. The monoclonal antibody of claim 1 , wherein the heavy chain variable region comprises SEQ ID NO: 19 and the light chain variable region comprises SEQ ID NO: 20.
36. The monoclonal antibody of claim 1 , wherein the heavy chain variable region comprises SEQ ID NO: 21 and the light chain variable region comprises SEQ ID NO: 22.
37. The monoclonal antibody of claim 1 , wherein the heavy chain variable region comprises SEQ ID NO: 23 and the light chain variable region comprises SEQ ID NO: 24.